Department of Obstetrics and Gynecology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.
Am J Obstet Gynecol. 2011 Sep;205(3):249.e1-8. doi: 10.1016/j.ajog.2011.06.024. Epub 2011 Jun 15.
The purpose was to examine in mice the efficacy of various polymeric-encapsulated C5a peptidase vaccine formulations in eliciting a long-term immune response and preventing group B streptococcus (GBS) infection.
C5a peptidase was encapsulated in semipermeable microspheres of poly(lactide-coglycolide) (PLGA). Female ICR mice were immunized with 0, 10, or 30 μg of encapsulated C5a peptidase within 2 different formulations of PLGA polymers. Booster doses were given at weeks 4 and 8. Antibody responses were measured by enzyme-linked immunosorbent assay at weeks 4, 8, 11, and 40. Vaginal challenges with GBS types 1a, III, and V were performed at week 12.
Thirty microgram doses of the 75:25 and 50:50 PLGA formulations generate the highest and most sustained C5a peptidase-specific immune responses. Mice that received encapsulated C5a peptidase were significantly protected from vaginal colonization compared with mice that received empty microspheres.
Encapsulated C5a peptidase elicited significant immune responses and protection against a GBS challenge. C5a peptidase microsphere encapsulation has potential as a GBS vaccine.
在小鼠中检验各种聚合物包封 C5a 肽酶疫苗制剂在引发长期免疫反应和预防 B 族链球菌（GBS）感染方面的疗效。
C5a 肽酶被包裹在聚（丙交酯-乙交酯）（PLGA）的半透性微球中。雌性 ICR 小鼠用 0、10 或 30μg 封装的 C5a 肽酶在 2 种不同的 PLGA 聚合物制剂中进行免疫接种。在第 4 和第 8 周给予加强剂量。在第 4、8、11 和 40 周通过酶联免疫吸附测定法测量抗体反应。在第 12 周进行 GBS 1a、III 和 V 型阴道挑战。
75:25 和 50:50 PLGA 制剂的 30μg 剂量可产生最高和最持久的 C5a 肽酶特异性免疫反应。与接受空微球的小鼠相比，接受封装的 C5a 肽酶的小鼠在阴道定植方面受到显著保护。
包封的 C5a 肽酶引发了显著的免疫反应，并能预防 GBS 挑战。C5a 肽酶微球包封具有作为 GBS 疫苗的潜力。
